BioRestorative Therapies, Inc. (BRTX) Income Statement
BRTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBRTX revenue and net income
Where BRTX's revenue goes
2025Each bar shows an amount and its share of revenue. BRTX kept −3,959.4% of revenue as net income.
BRTX profit margins
BRTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −10.3% | +44.3% | +36.1% | −5.4% |
| Gross profit | −9.9% | +41.0% | +34.3% | −0.9% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BRTX quarterly EPS vs estimates
BioRestorative Therapies beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 11, 2026 (estimate $-2.60).
BRTX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $359,700 | $401,000 | $145,800 | $119,800 | $46,000 | $77,000 | $130,000 | $111,000 | $81,000 | $36,355 |
| Cost of revenue | $23,844 | $28,072 | $165,735 | $120,544 | $205,205 | $0 | — | $0 | $259,260 | $102 |
| Gross profit | $335,856 | $372,928 | $145,800 | $119,800 | $46,000 | $77,000 | — | $111,000 | −$178,260 | $36,253 |
| Research & development | $10.1M | $5.3M | $4.0M | $3.5M | $729,058 | $876,829 | $1.7M | $1.5M | $2.2M | $2.9M |
| Sales, general & admin | $5.9M | $6.7M | $11.5M | $15.7M | $25.6M | $2.0M | $6.8M | $6.2M | $6.3M | $4.9M |
| Total operating expenses | $16.0M | $11.9M | $15.4M | $19.0M | $26.4M | $2.8M | $8.6M | $7.8M | $8.5M | $7.8M |
| Operating income | −$15.6M | −$11.6M | −$15.2M | −$18.9M | −$26.3M | −$2.8M | −$8.4M | −$7.6M | −$8.4M | −$7.8M |
| Interest income | $266,207 | $616,077 | $552,293 | $11,650 | — | — | — | — | — | — |
| Interest expense | — | — | — | $11,650 | $1.8M | $1.6M | $5.1M | $3.2M | $1.1M | $763,944 |
| Income before taxes | −$14.2M | −$9.0M | −$10.4M | −$13.2M | −$44.3M | −$11.3M | −$14.6M | −$12.5M | −$9.4M | −$8.6M |
| Income taxes | — | — | −$5 | −$479,256 | −$14.4M | $3.3M | — | −$1.6M | $1.0M | $717,339 |
| Net income | −$14.2M | −$9.0M | −$10.4M | −$13.2M | −$44.3M | −$11.3M | −$14.6M | −$12.5M | −$9.4M | −$8.6M |
| EBITDA | −$14.0M | −$8.8M | −$15.0M | −$13.1M | −$42.4M | −$9.5M | −$9.3M | −$9.1M | −$8.1M | −$7.6M |
| EPS (diluted) | −$1.59 | −$1.25 | −$3.51 | −$5.11 | −$17.00 | −$526.91 | −$0.76 | −$1.60 | −$1.64 | −$2.00 |
| Gross margin | 93.4% | 93.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | −220.1% | 99.7% |
| Operating margin | −4,350.1% | −2,881.6% | −10,439.5% | −15,745.8% | −57,191.0% | −3,574.1% | −6,486.2% | −6,889.8% | −10,338.6% | −21,447.6% |
| Net margin | −3,959.4% | −2,239.2% | −7,145.2% | −11,037.0% | −96,311.5% | −14,639.9% | −11,267.6% | −11,277.3% | −11,660.1% | −23,755.4% |
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23,170 | $19,600 | $11,800 | $303,300 | $25,000 | $43,300 | $233,600 | $89,100 | $35,000 | $19,300 | $30,700 | $64,500 |
| Cost of revenue | $7,385 | $1,636 | $10,570 | $8,729 | $2,909 | $3,339 | $18,243 | $6,490 | $42,713 | — | −$15,877 | $41,526 |
| Gross profit | $15,785 | $17,964 | $1,230 | $294,571 | $22,091 | $39,961 | $215,357 | $82,610 | $35,000 | — | $30,700 | $64,500 |
| Research & development | $1.9M | $2.6M | $2.6M | $2.2M | $1.7M | $1.7M | $1.3M | $1.3M | $1.1M | $680,631 | $809,824 | $902,891 |
| Sales, general & admin | $1.5M | $1.2M | $1.1M | $1.4M | $3.1M | $1.1M | $1.2M | $1.3M | $3.1M | $2.6M | $2.3M | $2.3M |
| Total operating expenses | $3.4M | $3.8M | $3.7M | $3.6M | $4.8M | $2.7M | $2.5M | $2.6M | $4.1M | $3.2M | $3.1M | $3.2M |
| Operating income | −$3.4M | −$3.8M | −$3.7M | −$3.3M | −$4.8M | −$2.7M | −$2.3M | −$2.5M | −$4.1M | −$3.2M | −$3.1M | −$3.1M |
| Interest income | $5,479 | $34,586 | $57,740 | $73,915 | $99,966 | $118,988 | $158,547 | $175,945 | $162,597 | — | $61,667 | $96,187 |
| Interest expense | — | — | — | — | — | — | — | — | $176,070 | — | $61,667 | $96,187 |
| Income before taxes | −$2.2M | −$3.2M | −$3.0M | −$2.7M | −$5.3M | −$1.6M | −$1.1M | −$4.0M | −$2.2M | −$2.8M | $4.8M | −$5.7M |
| Income taxes | — | — | — | — | — | $3 | — | $5 | −$3 | — | −$42,145 | −$96,187 |
| Net income | −$2.2M | −$3.2M | −$3.0M | −$2.7M | −$5.3M | −$1.6M | −$1.1M | −$4.0M | −$2.2M | −$2.8M | $4.8M | −$5.7M |
| EBITDA | −$2.1M | −$3.2M | −$3.0M | −$2.6M | −$5.3M | −$1.6M | −$1.0M | −$4.0M | −$2.2M | — | −$3.0M | −$5.7M |
| EPS (diluted) | −$0.12 | −$0.32 | −$0.33 | −$0.30 | −$0.64 | −$0.38 | −$0.01 | −$0.28 | −$0.59 | −$0.57 | −$0.64 | −$0.77 |
| Gross margin | 68.1% | 91.7% | 10.4% | 97.1% | 88.4% | 92.3% | 92.2% | 92.7% | 100.0% | — | 100.0% | 100.0% |
| Operating margin | −14,612.6% | −19,516.8% | −31,432.3% | −1,089.8% | −19,230.1% | −6,212.8% | −979.0% | −2,770.8% | −11,740.7% | −16,687.5% | −10,112.2% | −4,831.9% |
| Net margin | −9,298.3% | −16,365.5% | −25,748.1% | −875.8% | −21,359.2% | −3,778.6% | −467.2% | −4,521.4% | −6,352.2% | −14,638.4% | 15,531.8% | −8,851.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BRTX's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BRTX financial results
In fiscal year 2025 (ended December 31, 2025), BioRestorative Therapies reported revenue of $0.4 million, down 10.3% from the year before. It had a net loss of $14.2 million, a net profit margin of −3,959.4%. Diluted earnings per share came to −$1.59. Over five years revenue grew at an average rate of 36.1% a year.
See the BRTX stock overview for the latest quote and news, or the BRTX chart for price history and technical indicators.
BRTX income statement FAQ
What is BioRestorative Therapies's annual revenue?
BioRestorative Therapies reported total revenue of $0.4 million for fiscal year 2025, which ended on December 31, 2025. That was down 10.3% from $0.4 million the previous year.
Is BioRestorative Therapies profitable?
No. BioRestorative Therapies reported a net loss of $14.2 million in fiscal 2025, a net profit margin of −3,959.4%; its operating margin was −4,350.1%.
What is BioRestorative Therapies's gross margin?
BioRestorative Therapies's gross margin was 93.4% in fiscal 2025: for every $100 of revenue, BioRestorative Therapies kept $93 after the direct cost of its products and services.
How much does BioRestorative Therapies spend on research and development?
BioRestorative Therapies spent $10.1 million on research and development in fiscal 2025, 2,806.4% of revenue.
How fast is BioRestorative Therapies growing?
Revenue grew 36.1% a year on average over the last five fiscal years, from $0.1 million to $0.4 million.
What are BioRestorative Therapies's earnings per share?
BioRestorative Therapies earned $-1.59 per diluted share in fiscal 2025, compared with $-1.25 a year earlier.
When will BioRestorative Therapies report its next earnings?
BioRestorative Therapies is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does BioRestorative Therapies's fiscal year end?
BioRestorative Therapies's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.